title: Genetic variation in the progesterone receptor gene and ovarian cancer risk.
abstract: Evidence suggests a role for progesterone in ovarian cancer development. Progesterone exerts its effect on target cells by interacting with its receptor. Thus, genetic variations that may cause alterations in the biologic functions of the progesterone receptor can potentially contribute to individual susceptibility to ovarian cancer. Using a population-based, case-control study, the authors genotyped four polymorphisms in the progesterone receptor gene (+44C/T, +331G/A, G393G, V660L) and inferred haplotypes in 987 ovarian cancer cases and 1,034 controls living in New Hampshire and eastern Massachusetts (May 1992-November 2002). Odds ratios and 95% confidence intervals were calculated to evaluate associations with ovarian cancer. No associations were observed between the +44C/T, +331G/A, and G393G polymorphisms and ovarian cancer. However, an inverse association was observed between the V660L variant and ovarian cancer (odds ratio = 0.70, 95% confidence interval: 0.57, 0.85). Associations remained after adjustment for potential confounders. Five haplotypes occurred with greater than 5% frequency, and the haplotype carrying the V660L variant had a significant association with ovarian cancer (odds ratio = 0.76, 95% confidence interval: 0.62, 0.92). Associations were similar after stratifying by ovarian cancer histologies and risk factors.
authors.affiliation: Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. kterry@hsph.harvard.edu
authors.forename: Kathryn L
authors.initials: KL
authors.lastname: Terry
authors.forename: Immaculata
authors.initials: I
authors.lastname: De Vivo
authors.forename: Linda
authors.initials: L
authors.lastname: Titus-Ernstoff
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Sluss
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Cramer
mesh_terms: D000328:Adult; D000368:Aged; D000483:Alleles; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D015810:Linkage Disequilibrium; D016015:Logistic Models; D008404:Massachusetts / Q000453:epidemiology; D008875:Middle Aged; D009513:New Hampshire / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011980:Receptors, Progesterone / Q000235:genetics*; D012307:Risk Factors
chemical_list: D011980:Receptors, Progesterone
references.citation: Gynecol Oncol. 2000 Jun;77(3):429-32
references.pmid: 10831354
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-7
references.pmid: 15598772
references.citation: Am J Epidemiol. 2001 May 1;153(9):860-4
references.pmid: 11323316
references.citation: Carcinogenesis. 2001 May;22(5):717-21
references.pmid: 11323389
references.citation: Gynecol Oncol. 2001 Jul;82(1):116-21
references.pmid: 11426972
references.citation: Gynecol Oncol. 2001 Jul;82(1):127-38
references.pmid: 11426974
references.citation: Int J Cancer. 2001 Nov 20;95(6):394-7
references.pmid: 11668524
references.citation: Pharmacogenetics. 2001 Oct;11(7):635-8
references.pmid: 11668223
references.citation: J Natl Cancer Inst. 2002 Jan 2;94(1):32-8
references.pmid: 11773280
references.citation: J Natl Cancer Inst. 2002 Jan 2;94(1):50-60
references.pmid: 11773282
references.citation: Hum Hered. 2002;53(2):79-91
references.pmid: 12037407
references.citation: Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12263-8
references.pmid: 12218173
references.citation: J Clin Endocrinol Metab. 2002 Nov;87(11):5229-34
references.pmid: 12414896
references.citation: Am J Hum Genet. 2002 Dec;71(6):1386-94
references.pmid: 12439824
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):226-7
references.pmid: 12646513
references.citation: Zhonghua Fu Chan Ke Za Zhi. 2003 Oct;38(10):625-8
references.pmid: 14728868
references.citation: Gynecol Oncol. 2004 Jan;92(1):160-6
references.pmid: 14751152
references.citation: J Biol Chem. 1989 Mar 5;264(7):4207-11
references.pmid: 2917996
references.citation: Cell. 1992 May 15;69(4):703-13
references.pmid: 1586949
references.citation: Am J Epidemiol. 1992 Nov 15;136(10):1184-203
references.pmid: 1476141
references.citation: Biochim Biophys Acta. 1993 Nov 16;1216(2):289-92
references.pmid: 8241270
references.citation: Br J Cancer. 1995 Mar;71(3):451-5
references.pmid: 7880723
references.citation: Cancer Res. 1995 Jul 1;55(13):2743-5
references.pmid: 7796397
references.citation: Genes Dev. 1995 Sep 15;9(18):2266-78
references.pmid: 7557380
references.citation: Mol Biol Evol. 1995 Sep;12(5):921-7
references.pmid: 7476138
references.citation: Oncogene. 1996 Mar 7;12(5):999-1003
references.pmid: 8649817
references.citation: Cancer. 1997 May 15;79(10):1944-50
references.pmid: 9149021
references.citation: Br J Cancer. 1997;75(9):1398-9
references.pmid: 9155067
references.citation: Contraception. 1997 Sep;56(3):175-80
references.pmid: 9347209
references.citation: Am J Epidemiol. 2000 Aug 1;152(3):233-41
references.pmid: 10933270
references.citation: Lancet. 1998 Jan 10;351(9096):104-7
references.pmid: 9439495
references.citation: Br J Cancer. 1998 Jul;78(2):277
references.pmid: 9683307
references.citation: J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86
references.pmid: 9839517
references.citation: Genetics. 1964 Oct;50:757-82
references.pmid: 14221879
references.citation: Prostate. 2000 Apr 1;43(1):31-42
references.pmid: 10725863